2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-152947
    ELOVL6-IN-4 1170321-92-2 98.63%
    ELOVL6-IN-4 is a potent, selective, and orally active long chain fatty acid elongase 6 (ELOVL6) inhibitor with IC50s of 79 nM and 94 nM for human and mouse ELOVL6, respectively. ELOVL6-IN-4 shows excellent selectivity over the other human ELOVL subtypes (ELOVL1, -2, -3, and -5) and mouse ELOVL3.
    ELOVL6-IN-4
  • HY-15687A
    SAR407899 923359-38-0 99.60%
    SAR407899 is a selective, potent and ATP-competitive ROCK inhibitor, with an IC50 of 135 nM for ROCK-2, and Kis of 36 nM and 41 nM for human and rat ROCK-2, respectively. SAR407899 shows stable inhibition of migrasome formation.
    SAR407899
  • HY-15849A
    LP-533401 hydrochloride 1040526-12-2 98.02%
    LP-533401 hydrochloride is a tryptophan hydroxylase 1 inhibitor that regulates serotonin production in the gut.
    LP-533401 hydrochloride
  • HY-160093
    SQLE-IN-1 1019169-83-5 98.82%
    SQLE-IN-1 (compound 19) is a squalene epoxidase (SQLE) inhibitor. SQLE-IN-1 inhibits the proliferation and migration of Huh7 cells. SQLE-IN-1 inhibits the cell cholesterol generation. SQLE-IN-1 increases the expression of PTEN and inhibits PI3K and AKT.
    SQLE-IN-1
  • HY-113165A
    Isobutyryl-L-carnitine chloride 6920-31-6 ≥98.0%
    Isobutyryl-L-carnitine chloride is a product of the acyl-CoA dehydrogenases.
    Isobutyryl-L-carnitine chloride
  • HY-N0229S3
    L-Alanine-d4 18806-29-6 ≥99.0%
    L-Alanine-d4 is the deuterium labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.
    L-Alanine-d4
  • HY-N0420S1
    Succinic-2,2,3,3-d4 acid 14493-42-6 ≥99.0%
    Succinic-2,2,3,3-d4 acid is the deuterium labeled Succinic acid. Succinic acid is an intermediate product of the tricarboxylic acid cycle, as well as one of fermentation products of anaerobic metabolism.
    Succinic-2,2,3,3-d4 acid
  • HY-W017386
    3-Methyl-2-oxovaleric acid sodium 3715-31-9 ≥98.0%
    3-Methyl-2-oxovaleric acid sodium is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid sodium is a biomarker of mustard airway diseases (MADs) and uric acid stone.
    3-Methyl-2-oxovaleric acid sodium
  • HY-W142080
    α-Methyl-DL-tryptophan 153-91-3 99.92%
    α-Methyl-DL-tryptophan (α-Methyltryptophan), a tryptophan derivative, is a selective SLC6A14 blocker. In estrogen receptor (ER)-positive breast cancer cells, α-Methyl-DL-tryptophan inhibits mTOR and activates autophagy and apoptosis. α-Methyl-DL-tryptophan also has the effect of reducing weight.
    α-Methyl-DL-tryptophan
  • HY-15291
    MBX-2982 1037792-44-1 99.68%
    MBX-2982 is a selective, orally-available G protein-coupled receptor 119 (GPR119) agonist.
    MBX-2982
  • HY-NP135
    Oxidized low density lipoprotein (Human) ≥98.0%
    Oxidized low density lipoprotein (Human) (Human ox-LDL) is involved in atherogenesis. Oxidized low density lipoprotein (Human) induces endothelial dysfunction via cytoplasmic adapter protein TRAF3IP2. Oxidized low density lipoprotein (Human) can stimulate the activation of endothelial cells and the production of adhesion molecules, and inhibits eNOS activity and NO production. Oxidized low density lipoprotein (Human) can activate NLRP3 inflammasome in macrophages.
    Oxidized low density lipoprotein (Human)
  • HY-122141
    Glycohyocholic acid 32747-08-3 99.68%
    Glycohyocholic acid(GHCA) is a glycine-conjugated form of the primary bile acid hyocholic acid.
    Glycohyocholic acid
  • HY-111866
    PROTAC RIPK degrader-2 1801547-16-9 99.48%
    PROTAC RIPK degraders -2 is a non-peptide PROTAC based on von Hippel-Lindau and targets serine-threonine kinase RIPK2, which is highly selective to the degradation of RIPK2. PROTAC RIPK degrader-2 acts as an activator to increase cell death and activate ion channels in cancer cells. PROTAC RIPK degrader-2 also can inhibit protein interactions, such as receptors and ligands, involved in a variety of diseases, such as cancer and diabetes.
    PROTAC RIPK degrader-2
  • HY-142162
    LSN3318839 2764704-18-7 99.81%
    LSN3318839 is an orally active positive modulator of the glucagon-like peptide-1 receptor (GLP-1R). LSN3318839 can increase the secretion of insulin and has the effect of lowering blood sugar.
    LSN3318839
  • HY-103320A
    Calhex 231 hydrochloride 2387505-78-2 ≥98.0%
    Calhex 231 hydrochloride is a potent negative allosteric modulator that blocks (IC50 = 0.39 μM) increases in [3H]inositol phosphates elicited by activating the human wild-type CaSR transiently Ca2+-sensing receptor. Calhex 231 hydrochloride can be used in the study of traumatic hemorrhagic shock (THS) and diabetic cardiomyopathy (DCM).
    Calhex 231 hydrochloride
  • HY-112909A
    UAMC-3203 hydrochloride 2271358-65-5 ≥98.0%
    UAMC-3203 hydrochloride is a potent and selective Ferroptosis inhibitor with an IC50 of 12 nM.
    UAMC-3203 hydrochloride
  • HY-17613
    Evocalcet 870964-67-3 98.39%
    Evocalcet (KHK7580) is an orally active calcium sensing receptor (CaSR) agonist. Evocalcet inhibits the secretion of parathyroid hormone (PTH) from parathyroid gland cells. Evocalcet can be used for the research of hyperparathyroidism.
    Evocalcet
  • HY-P0177
    123C4 2034159-30-1 99.83%
    123C4 is a potent, selective and competitive agonist of the receptor tyrosine kinase EPHA4, with a Ki value of 0.65 μM.
    123C4
  • HY-109079A
    Abeprazan hydrochloride 1902954-87-3 99.87%
    Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases.
    Abeprazan hydrochloride
  • HY-10366
    BI-78D3 883065-90-5 99.85%
    BI-78D3 functions as a substrate competitive inhibitor of JNK, inhibit the JNK kinase activity (IC50=280 nM).
    BI-78D3
Cat. No. Product Name / Synonyms Application Reactivity